Neoadjuvant chemo then fertility-sparing surgery for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at whether giving chemotherapy before surgery (neoadjuvant chemotherapy) can shrink certain cervical cancers enough to allow fertility-sparing surgery. It may help some people avoid removing the uterus, while still treating the cancer effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have invasive cervical cancer confirmed by biopsy (adenocarcinoma, adenosquamous, or squamous type).
- Your tumor is between 2 cm and 4 cm based on MRI/scan measurements, and it is FIGO 2018 stage IB2.
- You are not in menopause yet and want to preserve future fertility.
- You have not had any prior treatment for the cancer in the area (no chemo, radiation, or cancer surgery).
- You can swallow and take study medicines, can consent, and your overall health is good enough for study visits (ECOG 0–2).
- You are not pregnant or breastfeeding, and you can use effective birth control during the study and for at least 1 year after fertility-sparing surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving chemotherapy combined with camrelizumab (a drug that helps the immune system fight cancer) before surgery can help women with early-stage cervical cancer who want to preserve their fertility. It is for patients whose tumors show a protein called PD-L1.
This trial tests a combination of immunotherapy (AK104) and standard chemotherapy before surgery for a certain type of early-stage cervical cancer. The goal is to see if this approach can help shrink the tumor enough to allow fertility-preserving surgery, so you may be able to keep your uterus.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This Phase 3 trial tests whether adding chemotherapy after surgery helps people with locally advanced cervical cancer, especially when prior treatment didn’t fully match standard guidelines. It looks at whether this “adjuvant” chemotherapy improves outcomes after neoadjuvant chemotherapy and an extensive hysterectomy.
This trial tests whether a combination of chemotherapy and immunotherapy (pembrolizumab) before surgery works better than standard chemoradiation for locally advanced cervical cancer. It may help shrink tumors more effectively.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.